Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 655 matching trials from the live ClinicalTrials.gov search.
Conditions
Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions
everolimus, carboplatin, pegylated liposomal doxorubicin hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Ovarian Cancer
Interventions
The current season's trivalent killed influenza vaccine
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Peritoneal Cancer, Recurrent Carcinoma of Ovary, Adenocarcinoma of Ovary
Interventions
Oregovomab, Niraparib
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Durham, North Carolina • Oklahoma City, Oklahoma • Charlottesville, Virginia
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
pemetrexed disodium
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
35
States / cities
Hinsdale, Illinois • Urbana, Illinois • Boston, Massachusetts + 26 more
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Cabozantinib S-malate, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
410
States / cities
Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 275 more
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
carboplatin, oglufanide disodium, paclitaxel, conventional surgery
Drug · Procedure
Lead sponsor
Cytran
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
19
States / cities
Glendale, California • Los Gatos, California • Stanford, California + 15 more
Completed Phase 4 Interventional Results available

Tumor Gene Expression in Women With Ovarian Cancer

NCT00817479
Conditions
Ovarian Cancer
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 59 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Malignant Ascites, Colorectal Adenocarcinoma, Peritoneal (Metastatic) Cancer, Appendiceal Adenocarcinoma
Interventions
ACM-CpG
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
atrasentan hydrochloride, doxil
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
6
States / cities
Macon, Georgia • Louisville, Kentucky • Germantown, Tennessee + 2 more
Conditions
Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer, Recurrent Ovarian Cancer
Interventions
WT1 Vaccine, Nivolumab, NY-ESO-1 Vaccine
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Ixabepilone, Bevacizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
New Haven, Connecticut • Baltimore, Maryland
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
chemotherapy, paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
21 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
5
States / cities
Orange, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Conditions
Cancer Ovaries, Cancer Peritoneal, Cancer, Fallopian Tube
Interventions
OMP-305B83, Paclitaxel
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Aurora, Colorado • Tampa, Florida • Charlotte, North Carolina + 4 more
Conditions
Advanced Malignant Mesothelioma, Localized Malignant Mesothelioma, Malignant Ascites, Primary Peritoneal Cavity Cancer, Recurrent Malignant Mesothelioma
Interventions
etanidazole, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Malignant Pleural Effusion, Malignant Ascites
Interventions
Tocilizumab
Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Conditions
High Grade Serous Ovarian, Fallopian Tube, Primary Peritoneal Cancer
Interventions
Carboplatin and Paclitaxel, Nivolumab, Cytoreductive surgery, Ipilimumab
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Malignant Gastrointestinal Neoplasm, Malignant Peritoneal Neoplasm
Interventions
Management of Therapy Complications Fitbit Zip (portable pedometer device), Questionnaire Administration, Quality-of-Life Assessment
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
oregovomab
Biological
Lead sponsor
AltaRex
Industry
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
15
States / cities
Newport Beach, California • Fort Myers, Florida • Orlando, Florida + 11 more
Conditions
Peritoneal Neoplasms, Retroperitoneal Neoplasms, Gastrointestinal Neoplasms, Adenocarcinoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Adrenocortical Carcinoma, Wilms Tumor, Rhabdomyosarcoma, Desmoplastic Small Round Cell Tumor
Interventions
CHPP of Cisplatin, Abdominal Surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Conditions
Ovarian Cancer
Interventions
catumaxomab
Drug
Lead sponsor
Neovii Biotech
Industry
Eligibility
18 Years and older · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
12
States / cities
Tucson, Arizona • Stanford, California • Orlando, Florida + 9 more
Conditions
Gastrointestinal Cancer, Peritoneal Carcinomatosis
Interventions
Pafolacianine (CYTALUX) with intraoperative fluorescent near-infrared (NIR) imaging
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orange, California
Conditions
Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions
Carboplatin, Gynecological Surgical Procedure, Laboratory Biomarker Analysis, Paclitaxel, pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine
Drug · Procedure · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Cancer
Interventions
floxuridine, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York